High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer
Takuya Shiraishi(National Cancer Center Hospital East), Yasuhiro Matsumura(The Rogosin Institute), Takeshi Sasaki(Sapporo Medical University), Yuji Nishizawa(National Cancer Center Hospital East), Sinji Saijou(National Cancer Research Institute), Yoshikatsu Koga, Masahiro Yasunaga(Japan Clinical Cancer Research Organization), Masaaki Ito(National Cancer Centre Japan), Koji Ikeda(Japan Society of Laparoscopic Colorectal Surgery), Motohiro Kojima(Chiba Cancer Center), Ryo Tsumura(National Cancer Center Hospital East), Genichiro Ishii(National Cancer Center Hospital East), Yuichiro Tsukada(National Cancer Center Hospital East)
Cited by 15
Related Papers
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
|PubMed|1986|6.8k
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
|Journal of Controlled Release|2000|6.5k
Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease
|Journal of the American College of Cardiology|2015|374
HD4, a 180 kDa Bullous Pemphigoid Antigen, Is a Major Transmembrane Glycoprotein of the Hemidesmosome1
|The Journal of Biochemistry|1993|145